ClinicalTrials.gg
CompletedNCT01923168Updated Sep 14, 2018Results posted

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

A Phase 2 interventional study of alpelisib and buparlisib in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 87 sites in 17 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.

Enrollment
3rd of 38
340 · median 44
Started
2014
with 6 others
Phase 2
15 of 38
2 open now
Registered
7th of 38
by date
Lead sponsor
18 of 38
Novartis Pharmaceuticals

Among the 38 studies testing alpelisib in Breast Neoplasms, this one is the 3rd largest by enrollment, is one of 7 that started in 2014, is one of 15 in phase 2, and was the 7th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About alpelisib

Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing alpelisib in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study was to determine whether treatment with a PI3K inhibitor plus letrozole led to an increase in pathologic clinical response and Objective Response Rate compared to treatment with placebo plus letrozole in patients with Breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • BYL719
  • alpelisib
  • Breast Cancer
  • BKM120
  • buparlisib
  • Pathological Complete Response
  • neoadjuvant
  • hormone receptor-positive
  • HER2 negative
  • Objective Response Rate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is an adult, female ≥ 18 years old at the time of
  2. Patient has a and/or cytologically confirmed diagnosis of breast cancer
  3. Patient is .
  4. Patient has T1c-T3, any N, M0, operable breast cancer
  5. Patients must have
  6. Patient has diagnostic available for the analysis of PIK3CA mutation and Ki67 level.
  7. Patient has estrogen-receptor and/or progesterone positive breast cancer as per local laboratory testing
  8. Patient has negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0 or 1+ as per local laboratory testing

Exclusion criteria

Exclusion Criteria:

  1. Patient has locally recurrent or disease
  2. Patient has received any systemic therapy (e.g. chemotherapy, targeted therapy, immunotherapy) or radiotherapy for current breast cancer disease before randomization.
  3. Patient with type 1 diabetes mellitus or not adequately controlled type 2 diabetes mellitus
  4. History of acute pancreatitis within 1 year of study entry
  5. Uncontrolled hypertension
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
340 participants (actual)

Study arms

  • Experimental
    Alpelisib + Letrozole

    Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.

    Drug: alpelisib

  • Experimental
    Buparlisib + Letrozole

    Participants took buparlisib 100 mg once daily or 5 days on/2 days off plus letrozole 2.5 mg once daily.

    Drug: buparlisib

  • Placebo comparator
    Placebo + Letrozole

    Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.

    Drug: Placebo

Interventions

  • BYL719 + Letrozole

    Also known as: BYL719

  • BKM120 + Letrozole

    Also known as: BKM120

  • DrugPlacebo

    Placebo (of BYL719 or BKM120) + Letrozole

    Also known as: BYL719 Placebo, BKM120 Placebo

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort

    Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy, or who did not receive surgery for any reason, or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate.

    Time frame: After 24 weeks of treatment

  2. Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Wild-type Cohort

    Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy, or who did not receive surgery for any reason, or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate.

    Time frame: After 24 weeks of treatment

  3. Objective Response Rate Per Investigator Assessment According to RECIST 1.1 for Alpelisib vs. Placebo - PIK3CA Mutant Cohort

    Objective Response Rate (ORR) defined as the proportion of patients with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) 1.1. BOR was assessed per MRI or Ultrasound and defined as per RECIST 1.1 as CR for a disappearance of all non-nodal target lesions (TL)/non-target lesions (NTL) and a reduction in short axis to \< 10 mm of any pathological lymph nodes assigned as TL/NTL and no new lesion; as PR if not qualifying for CR but with a decrease from baseline ≥ 30% in the sum of diameter of all TL, no progression of NTL and no new lesion.

    Time frame: After 24 weeks of treatment

  4. Objective Response Rate According to RECIST 1.1 Per Investigator Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort

    Objective Response Rate (ORR) defined as the proportion of patients with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) 1.1. BOR was assessed per MRI or Ultrasound and defined as per RECIST 1.1 as CR for a disappearance of all non-nodal target lesions (TL)/non-target lesions (NTL) and a reduction in short axis to \< 10 mm of any pathological lymph nodes assigned as TL/NTL and no new lesion; as PR if not qualifying for CR but with a decrease from baseline ≥ 30% in the sum of diameter of all TL, no progression of NTL and no new lesion.

    Time frame: After 24 weeks of treatment

Secondary outcomes

  1. pCR and Objective Response Rate According to RECIST 1.1 Criteria Per Investigator Assessment for Alpelisib vs. Placebo in PIK3CA Mutant Cohort Based on ctDNA

    pCR and Objective response rate according to RECIST 1.1 per investigator assessment after 24 weeks of treatment

    Time frame: After 24 weeks of treatment

  2. pCR and Objective Response Rate According to RECIST 1.1 Criteria Per Investigator Assessment for Alpelisib vs. Placebo in PIK3CA Wild-type Cohort Based on ctDNA

    pCR and Objective response rate according to RECIST 1.1 per investigator assessment after 24 weeks of treatment

    Time frame: After 24 weeks of treatment

  3. Rate of Breast Conserving Surgery for Alpelisib vs. Placebo - PIK3CA Mutant Cohort

    Breast conserving surgery is defined for participants who underwent surgery and did not have a mastectomy. The row "no surgery" provides the number of patients who did not undergo surgery at all for various reasons.

    Time frame: After 24 weeks of treatment

  4. Rate of Breast Conserving Surgery for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort

    Breast conserving surgery is defined as the percentage of participants with no mastectomy following completion of 24 weeks of treatment. Breast conserving surgery is defined for participants who underwent surgery and did not have a mastectomy. The row "no surgery" provides the number of patients who did not undergo surgery at all for various reasons.

    Time frame: After 24 weeks of treatment

  5. Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Responders as Per pCR

    Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Responders as Per pCR

    Time frame: Baseline, Cycle 1 Day 15 (each cycle is 28 days) and surgery (End of Treatment (EOT) expected after 24 weeks of treatment)

  6. Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Non-responders as Per pCR

    Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Non-responders as Per pCR.

    Time frame: Baseline, Cycle 1 Day 15 (each cycle is 28 days ) and surgery (End of Treatment (EOT) expected after 24 weeks of treatment)

  7. Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort: Responders as Per pCR

    Association between pCR and changes in Ki67 from baseline for alpelisib vs. placebo - PIK3CA wild-type cohort: responders as per pCR

    Time frame: Baseline, Cycle 1 Day 15 (each cycle is 28 days) and surgery (End of Treatment (EOT) expected after 24 weeks of treatment)

  8. Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort: Non-responders as Per pCR

    Association between pCR and changes in Ki67 from baseline for alpelisib vs. placebo - PIK3CA wild-type cohort: non-responders as per pCR

    Time frame: Baseline, Cycle 1 Day 15 (each cycle is 28 days) and surgery (End of Treatment (EOT) expected after 24 weeks of treatment)

  9. Preoperative Endocrine Prognostic Index (PEPI) Response as Per Central Assessment for Alpelisib vs. Placebo - PIK3CA Mutant Cohort

    Preoperative endocrine prognostic index (PEPI) response as per central assessment for alpelisib vs. placebo - PIK3CA mutant cohort. The total PEPI score assigned to each patient is the sum of the risk points derived from the pT stage, pN stage, Ki67 level, and ER status of the surgical specimen (Ellis et al, Contemp Clin Trials 2008). The PEPI score ranges from 0 to to 12, and a higher score means a worse outcome. PEPI response is defined as a PEPI score of 0.

    Time frame: At the time of surgery (expected after 24 weeks of treatment)

  10. Preoperative Endocrine Prognostic Index (PEPI) Response as Per Central Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort

    Preoperative endocrine prognostic index (PEPI) response as per central assessment for alpelisib vs. placebo - PIK3CA wild-type cohort. The total PEPI score assigned to each patient is the sum of the risk points derived from the pT stage, pN stage, Ki67 level, and ER status of the surgical specimen (Ellis et al, Contemp Clin Trials 2008). The PEPI score ranges from 0 to to 12, and a higher score means a worse outcome. PEPI response is defined as a PEPI score of 0.

    Time frame: At the time of surgery (expected after 24 weeks of treatment)

  11. Alpelisib PK Parameters: AUC0-24, AUClast at Cycle 1 Day 1

    Summary of primary PK parameters for alpelisib plasma concentration

    Time frame: 0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 1 Day 1 (each cycle is 28 days)

  12. Alpelisib PK Parameter: Cmax at Cycle 1 Day 1

    Summary of primary PK parameters for alpelisib plasma concentration

    Time frame: Cycle 1 Day 1 (each cycle is 28 days)

  13. Alpelisib and PK Parameter: Tmax at Cycle 1 Day 1

    Summary of primary PK parameters for alpelisib plasma concentration

    Time frame: Cycle 1 Day 1 (each cycle is 28 days)

  14. Alpelisib PK Parameters: AUC0-24, AUClast at Cycle 4 Day 1

    Summary of primary PK parameters for alpelisib plasma concentration

    Time frame: 0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 4 Day 1 (each cycle is 28 days)

  15. Alpelisib PK Parameter: Cmax at Cycle 4 Day 1

    Summary of primary PK parameters for alpelisib plasma concentration

    Time frame: Cycle 4 Day 1 (each cycle is 28 days)

  16. Alpelisib PK Parameter: Tmax at Cycle 4 Day 1

    Summary of primary PK parameters for alpelisib plasma concentration

    Time frame: Cycle 4 Day 1 (each cycle is 28 days)

  17. Letrozole and PK Parameters: AUC0-24, AUClast at Cycle 1 Day 1

    Summary of primary PK parameters for Letrozole plasma concentration

    Time frame: 0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 1 Day 1 (each cycle is 28 days)

  18. Letrozole PK Parameter: Cmax at Cycle 1 Day 1

    Summary of primary PK parameters for letrozole plasma concentration

    Time frame: Cycle 1 Day 1 (each cycle is 28 days)

  19. Letrozole PK Parameter: Tmax at Cycle 1 Day 1

    Summary of primary PK parameters for letrozole plasma concentration

    Time frame: Cycle 1 Day 1 (each cycle is 28 days)

  20. Letrozole PK Parameters: AUC0-24, AUClast at Cycle 4 Day 1

    Summary of primary PK parameters for Letrozole plasma concentration

    Time frame: 0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 4 Day 1 (each cycle is 28 days)

  21. Letrozole PK Parameter: Cmax at Cycle 4 Day 1

    Summary of primary PK parameters for letrozole plasma concentration

    Time frame: Cycle 4 Day 1 (each cycle is 28 days)

  22. Letrozole PK Parameter: Tmax at Cycle 4 Day 1

    Summary of primary PK parameters for letrozole plasma concentration

    Time frame: Cycle 4 Day 1 (each cycle is 28 days)

  23. Buparlisib PK Parameters: AUC0-24, AUClast at Cycle 1 Day 1

    Summary of primary PK parameters for Buparlisib plasma concentration

    Time frame: 0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 1 Day 1 (each cycle is 28 days)

  24. Buparlisib PK Parameter: Cmax at Cycle 1 Day 1

    Summary of primary PK parameters for buparlisib plasma concentration

    Time frame: Cycle 1 Day 1 (each cycle is 28 days)

  25. Buparlisib PK Parameter: Tmax at Cycle 1 Day 1

    Summary of primary PK parameters for buparlisib plasma concentration

    Time frame: Cycle 1 Day 1 (each cycle is 28 days)

  26. Buparlisib PK Parameter: AUClast at Cycle 4 Day 1

    Summary of primary PK parameters for Buparlisib plasma concentration

    Time frame: 0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 4 Day 1 (each cycle is 28 days)

  27. Buparlisb PK Parameter: Cmax at Cycle 4 Day 1

    Summary of primary PK parameters for buparlisib plasma concentration

    Time frame: Cycle 4 Day 1 (each cycle is 28 days)

  28. Buparlisib PK Parameter: Tmax at Cycle 4 Day 1

    Summary of primary PK parameters for buparlisib plasma concentration

    Time frame: Cycle 4 Day 1 (each cycle is 28 days)

07

Results

Posted Sep 14, 2018

Participant flow

A total of approximately 320 patients were planned to be randomized: this was based on 60 patients per arm in each cohort (PIK3CA mutant and PIK3CA wild-type) for the alpelisib+letrozole and placebo+letrozole arms, plus the estimated number of patients randomized to buparlisib+letrozole arm at the time this arm was discontinued.

Participant flow — Overall Study
MilestoneAlpelisib + LetrozoleBuparlisib + LetrozolePlacebo + Letrozole
Started13183126
Completed9444109
Not completed373917
Withdrew: Protocol violation110
Withdrew: Subject/guardian decision14144
Withdrew: Adverse event12120
Withdrew: Physician decision695
Withdrew: Progressive disease437
Withdrew: Death001

Outcome measures

PrimaryPathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort

Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy, or who did not receive surgery for any reason, or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate.

Time frame:
After 24 weeks of treatment
Reported as:
Number · Percentage of Participants
Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort
Percentage of ParticipantsAlpelisib + LetrozolePlacebo + Letrozole
Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort1.7 (0.2 to 6.3)3.0 (0.8 to 7.7)
Statistical analysis
  • Alpelisib + Letrozole vs Placebo + Letrozole · Posterior mean diff. & credible interval · p = 0.282 · Mean difference (final values): -1.3 · 80% CI -4.5 to 1.7
PrimaryPathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Wild-type Cohort

Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy, or who did not receive surgery for any reason, or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate.

Time frame:
After 24 weeks of treatment
Reported as:
Number · Percentage of Participants
Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Wild-type Cohort
Percentage of ParticipantsAlpelisib + LetrozolePlacebo + Letrozole
Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Wild-type Cohort2.8 (0.8 to 7.3)1.7 (0.2 to 6.4)
Statistical analysis
  • Alpelisib + Letrozole vs Placebo + Letrozole · Posterior mean difference · p = 0.697 · Mean difference (final values): 1.1 · 80% CI -1.9 to 4.2Posterior mean difference
PrimaryObjective Response Rate Per Investigator Assessment According to RECIST 1.1 for Alpelisib vs. Placebo - PIK3CA Mutant Cohort

Objective Response Rate (ORR) defined as the proportion of patients with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) 1.1. BOR was assessed per MRI or Ultrasound and defined as per RECIST 1.1 as CR for a disappearance of all non-nodal target lesions (TL)/non-target lesions (NTL) and a reduction in short axis to \< 10 mm of any pathological lymph nodes assigned as TL/NTL and no new lesion; as PR if not qualifying for CR but with a decrease from baseline ≥ 30% in the sum of diameter of all TL, no progression of NTL and no new lesion.

Time frame:
After 24 weeks of treatment
Reported as:
Number · Percentage of Participants
Objective Response Rate Per Investigator Assessment According to RECIST 1.1 for Alpelisib vs. Placebo - PIK3CA Mutant Cohort
Percentage of ParticipantsAlpelisib + LetrozolePlacebo + Letrozole
Objective Response Rate Per Investigator Assessment According to RECIST 1.1 for Alpelisib vs. Placebo - PIK3CA Mutant Cohort43.3 (34.6 to 52.4)44.8 (36.5 to 53.3)
Statistical analysis
  • Alpelisib + Letrozole vs Placebo + Letrozole · Posterior mean diff. & credible interval · p = 0.435 · Mean difference (final values): -1.4 · 80% CI -12.5 to 9.7
PrimaryObjective Response Rate According to RECIST 1.1 Per Investigator Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort

Objective Response Rate (ORR) defined as the proportion of patients with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) 1.1. BOR was assessed per MRI or Ultrasound and defined as per RECIST 1.1 as CR for a disappearance of all non-nodal target lesions (TL)/non-target lesions (NTL) and a reduction in short axis to \< 10 mm of any pathological lymph nodes assigned as TL/NTL and no new lesion; as PR if not qualifying for CR but with a decrease from baseline ≥ 30% in the sum of diameter of all TL, no progression of NTL and no new lesion.

Time frame:
After 24 weeks of treatment
Reported as:
Number · Percentage of Participants
Objective Response Rate According to RECIST 1.1 Per Investigator Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort
Percentage of ParticipantsAlpelisib + LetrozolePlacebo + Letrozole
Objective Response Rate According to RECIST 1.1 Per Investigator Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort63.4 (55.1 to 71.0)61.0 (51.8 to 69.6)
Statistical analysis
  • Alpelisib + Letrozole vs Placebo + Letrozole · Posterior mean diff. & credible interval · p = 0.611 · Mean difference (final values): 2.4 · 80% CI -8.4 to 13.2
SecondarypCR and Objective Response Rate According to RECIST 1.1 Criteria Per Investigator Assessment for Alpelisib vs. Placebo in PIK3CA Mutant Cohort Based on ctDNA

pCR and Objective response rate according to RECIST 1.1 per investigator assessment after 24 weeks of treatment

Time frame:
After 24 weeks of treatment

No measurements were reported for this outcome.

SecondarypCR and Objective Response Rate According to RECIST 1.1 Criteria Per Investigator Assessment for Alpelisib vs. Placebo in PIK3CA Wild-type Cohort Based on ctDNA

pCR and Objective response rate according to RECIST 1.1 per investigator assessment after 24 weeks of treatment

Time frame:
After 24 weeks of treatment

No measurements were reported for this outcome.

SecondaryRate of Breast Conserving Surgery for Alpelisib vs. Placebo - PIK3CA Mutant Cohort

Breast conserving surgery is defined for participants who underwent surgery and did not have a mastectomy. The row "no surgery" provides the number of patients who did not undergo surgery at all for various reasons.

Time frame:
After 24 weeks of treatment
Reported as:
Number · Percentage of participants
Rate of Breast Conserving Surgery for Alpelisib vs. Placebo - PIK3CA Mutant Cohort
Percentage of participantsAlpelisib + LetrozolePlacebo + Letrozole
Breast conserving surgery56.7 (47.6 to 65.4)50.7 (42.2 to 59.2)
No Surgery15.0 (9.3 to 22.6)9.0 (4.8 to 15.2)
SecondaryRate of Breast Conserving Surgery for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort

Breast conserving surgery is defined as the percentage of participants with no mastectomy following completion of 24 weeks of treatment. Breast conserving surgery is defined for participants who underwent surgery and did not have a mastectomy. The row "no surgery" provides the number of patients who did not undergo surgery at all for various reasons.

Time frame:
After 24 weeks of treatment
Reported as:
Number · Percentage of participants
Rate of Breast Conserving Surgery for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort
Percentage of participantsAlpelisib + LetrozolePlacebo + Letrozole
Breast conserving surgery50.7 (42.5 to 58.9)62.7 (53.6 to 71.2)
No Surgery18.3 (12.5 to 25.6)8.5 (4.5 to 15.2)
SecondaryAssociation Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Responders as Per pCR

Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Responders as Per pCR

Time frame:
Baseline, Cycle 1 Day 15 (each cycle is 28 days) and surgery (End of Treatment (EOT) expected after 24 weeks of treatment)
Reported as:
Median · Percentage of positive cells
Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Responders as Per pCR
Percentage of positive cellsAlpelisib + LetrozolePlacebo + Letrozole
Baseline5.0 (5 to 5)11.0 (5 to 17)
C1D15: % change from Baseline-80.0 (-80 to -80)80.0 (80 to 80)
SecondaryAssociation Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Non-responders as Per pCR

Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Non-responders as Per pCR.

Time frame:
Baseline, Cycle 1 Day 15 (each cycle is 28 days ) and surgery (End of Treatment (EOT) expected after 24 weeks of treatment)
Reported as:
Median · Percentage of positive cells
Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Mutant Cohort: Non-responders as Per pCR
Percentage of positive cellsAlpelisib + LetrozolePlacebo + Letrozole
Baseline14.0 (0 to 82)13.0 (3 to 89)
C1D15 % change from Baseline-62.5 (-97 to 467)-60.0 (-96 to 733)
EOT % change from Baseline-51.2 (-94 to 400)-60.0 (-97 to 223)
SecondaryAssociation Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort: Responders as Per pCR

Association between pCR and changes in Ki67 from baseline for alpelisib vs. placebo - PIK3CA wild-type cohort: responders as per pCR

Time frame:
Baseline, Cycle 1 Day 15 (each cycle is 28 days) and surgery (End of Treatment (EOT) expected after 24 weeks of treatment)
Reported as:
Median · Percentage of positive cells
Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort: Responders as Per pCR
Percentage of positive cellsAlpelisib + LetrozolePlacebo + Letrozole
Baseline16.5 (3 to 30)20.0 (20 to 20)
C1D15: % change from Baseline-80.0 (-80 to -80)—
EOT % change from Baseline-45.0 (-90 to 0)—
SecondaryAssociation Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort: Non-responders as Per pCR

Association between pCR and changes in Ki67 from baseline for alpelisib vs. placebo - PIK3CA wild-type cohort: non-responders as per pCR

Time frame:
Baseline, Cycle 1 Day 15 (each cycle is 28 days) and surgery (End of Treatment (EOT) expected after 24 weeks of treatment)
Reported as:
Median · Percentage of positive cells
Association Between pCR and Changes in Ki67 From Baseline for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort: Non-responders as Per pCR
Percentage of positive cellsAlpelisib + LetrozolePlacebo + Letrozole
Baseline16.0 (3 to 60)18.0 (4 to 85)
C1D15 % change from Baseline-60.0 (-97 to 220)-52.0 (-93 to 50)
EOT % change from Baseline-60.0 (-90 to 190)-71.1 (-100 to 250)
SecondaryPreoperative Endocrine Prognostic Index (PEPI) Response as Per Central Assessment for Alpelisib vs. Placebo - PIK3CA Mutant Cohort

Preoperative endocrine prognostic index (PEPI) response as per central assessment for alpelisib vs. placebo - PIK3CA mutant cohort. The total PEPI score assigned to each patient is the sum of the risk points derived from the pT stage, pN stage, Ki67 level, and ER status of the surgical specimen (Ellis et al, Contemp Clin Trials 2008). The PEPI score ranges from 0 to to 12, and a higher score means a worse outcome. PEPI response is defined as a PEPI score of 0.

Time frame:
At the time of surgery (expected after 24 weeks of treatment)
Reported as:
Number · Number of participants
Preoperative Endocrine Prognostic Index (PEPI) Response as Per Central Assessment for Alpelisib vs. Placebo - PIK3CA Mutant Cohort
Number of participantsAlpelisib + LetrozolePlacebo + Letrozole
Preoperative Endocrine Prognostic Index (PEPI) Response as Per Central Assessment for Alpelisib vs. Placebo - PIK3CA Mutant Cohort10
SecondaryPreoperative Endocrine Prognostic Index (PEPI) Response as Per Central Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort

Preoperative endocrine prognostic index (PEPI) response as per central assessment for alpelisib vs. placebo - PIK3CA wild-type cohort. The total PEPI score assigned to each patient is the sum of the risk points derived from the pT stage, pN stage, Ki67 level, and ER status of the surgical specimen (Ellis et al, Contemp Clin Trials 2008). The PEPI score ranges from 0 to to 12, and a higher score means a worse outcome. PEPI response is defined as a PEPI score of 0.

Time frame:
At the time of surgery (expected after 24 weeks of treatment)
Reported as:
Number · Number of participants
Preoperative Endocrine Prognostic Index (PEPI) Response as Per Central Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort
Number of participantsAlpelisib + LetrozolePlacebo + Letrozole
Preoperative Endocrine Prognostic Index (PEPI) Response as Per Central Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort11
SecondaryAlpelisib PK Parameters: AUC0-24, AUClast at Cycle 1 Day 1

Summary of primary PK parameters for alpelisib plasma concentration

Time frame:
0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 1 Day 1 (each cycle is 28 days)
Reported as:
Geometric mean · ng*hr/mL
Alpelisib PK Parameters: AUC0-24, AUClast at Cycle 1 Day 1
ng*hr/mLAlpelisib + Letrozole
AUC0-2430800 ± 20.6
AUClast27300 ± 68.6
SecondaryAlpelisib PK Parameter: Cmax at Cycle 1 Day 1

Summary of primary PK parameters for alpelisib plasma concentration

Time frame:
Cycle 1 Day 1 (each cycle is 28 days)
Reported as:
Geometric mean · ng/mL
Alpelisib PK Parameter: Cmax at Cycle 1 Day 1
ng/mLAlpelisib + Letrozole
Alpelisib PK Parameter: Cmax at Cycle 1 Day 13160 ± 25.3
SecondaryAlpelisib and PK Parameter: Tmax at Cycle 1 Day 1

Summary of primary PK parameters for alpelisib plasma concentration

Time frame:
Cycle 1 Day 1 (each cycle is 28 days)
Reported as:
Median · HR
Alpelisib and PK Parameter: Tmax at Cycle 1 Day 1
HRAlpelisib + Letrozole
Alpelisib and PK Parameter: Tmax at Cycle 1 Day 12.93 (1 to 6)
SecondaryAlpelisib PK Parameters: AUC0-24, AUClast at Cycle 4 Day 1

Summary of primary PK parameters for alpelisib plasma concentration

Time frame:
0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 4 Day 1 (each cycle is 28 days)
Reported as:
Geometric mean · ng*hr/mL
Alpelisib PK Parameters: AUC0-24, AUClast at Cycle 4 Day 1
ng*hr/mLAlpelisib + Letrozole
AUC0-2438000 ± 13.2
AUClast38000 ± 13.1
SecondaryAlpelisib PK Parameter: Cmax at Cycle 4 Day 1

Summary of primary PK parameters for alpelisib plasma concentration

Time frame:
Cycle 4 Day 1 (each cycle is 28 days)
Reported as:
Geometric mean · ng/mL
Alpelisib PK Parameter: Cmax at Cycle 4 Day 1
ng/mLAlpelisib + Letrozole
Alpelisib PK Parameter: Cmax at Cycle 4 Day 13260 ± 26.7
SecondaryAlpelisib PK Parameter: Tmax at Cycle 4 Day 1

Summary of primary PK parameters for alpelisib plasma concentration

Time frame:
Cycle 4 Day 1 (each cycle is 28 days)
Reported as:
Median · hr
Alpelisib PK Parameter: Tmax at Cycle 4 Day 1
hrAlpelisib + Letrozole
Alpelisib PK Parameter: Tmax at Cycle 4 Day 12.99 (2.98 to 3)
SecondaryLetrozole and PK Parameters: AUC0-24, AUClast at Cycle 1 Day 1

Summary of primary PK parameters for Letrozole plasma concentration

Time frame:
0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 1 Day 1 (each cycle is 28 days)
Reported as:
Geometric mean · ng*hr/mL
Letrozole and PK Parameters: AUC0-24, AUClast at Cycle 1 Day 1
ng*hr/mLAlpelisib + LetrozolePlacebo + Letrozole
AUC0-24433 ± 36.3427 ± 28.8
AUClast314 ± 96.9347 ± 49.6
SecondaryLetrozole PK Parameter: Cmax at Cycle 1 Day 1

Summary of primary PK parameters for letrozole plasma concentration

Time frame:
Cycle 1 Day 1 (each cycle is 28 days)
Reported as:
Geometric mean · ng/mL
Letrozole PK Parameter: Cmax at Cycle 1 Day 1
ng/mLAlpelisib + LetrozolePlacebo + Letrozole
Letrozole PK Parameter: Cmax at Cycle 1 Day 130.2 ± 33.228 ± 42.3
SecondaryLetrozole PK Parameter: Tmax at Cycle 1 Day 1

Summary of primary PK parameters for letrozole plasma concentration

Time frame:
Cycle 1 Day 1 (each cycle is 28 days)
Reported as:
Median · hr
Letrozole PK Parameter: Tmax at Cycle 1 Day 1
hrAlpelisib + LetrozolePlacebo + Letrozole
Letrozole PK Parameter: Tmax at Cycle 1 Day 11.03 (1 to 3)2.25 (1 to 24.5)
SecondaryLetrozole PK Parameters: AUC0-24, AUClast at Cycle 4 Day 1

Summary of primary PK parameters for Letrozole plasma concentration

Time frame:
0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 4 Day 1 (each cycle is 28 days)
Reported as:
Geometric mean · ng*hr/mL
Letrozole PK Parameters: AUC0-24, AUClast at Cycle 4 Day 1
ng*hr/mLAlpelisib + LetrozolePlacebo + Letrozole
AUC0-241280 ± 181810 ± 33.1
AUClast1280 ± 17.91440 ± 66.7
SecondaryLetrozole PK Parameter: Cmax at Cycle 4 Day 1

Summary of primary PK parameters for letrozole plasma concentration

Time frame:
Cycle 4 Day 1 (each cycle is 28 days)
Reported as:
Geometric mean · ng/mL
Letrozole PK Parameter: Cmax at Cycle 4 Day 1
ng/mLAlpelisib + LetrozolePlacebo + Letrozole
Letrozole PK Parameter: Cmax at Cycle 4 Day 175.6 ± 6.84103 ± 30
SecondaryLetrozole PK Parameter: Tmax at Cycle 4 Day 1

Summary of primary PK parameters for letrozole plasma concentration

Time frame:
Cycle 4 Day 1 (each cycle is 28 days)
Reported as:
Median · hr
Letrozole PK Parameter: Tmax at Cycle 4 Day 1
hrAlpelisib + LetrozolePlacebo + Letrozole
Letrozole PK Parameter: Tmax at Cycle 4 Day 12 (1 to 3)1.17 (1 to 6)
SecondaryBuparlisib PK Parameters: AUC0-24, AUClast at Cycle 1 Day 1

Summary of primary PK parameters for Buparlisib plasma concentration

Time frame:
0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 1 Day 1 (each cycle is 28 days)
Reported as:
Geometric mean · ng*hr/mL
Buparlisib PK Parameters: AUC0-24, AUClast at Cycle 1 Day 1
ng*hr/mLBuparlisib + Letrozole
AUC0-246420 ± 60
AUClast4820 ± 123
SecondaryBuparlisib PK Parameter: Cmax at Cycle 1 Day 1

Summary of primary PK parameters for buparlisib plasma concentration

Time frame:
Cycle 1 Day 1 (each cycle is 28 days)
Reported as:
Geometric mean · ng/mL
Buparlisib PK Parameter: Cmax at Cycle 1 Day 1
ng/mLBuparlisib + Letrozole
Buparlisib PK Parameter: Cmax at Cycle 1 Day 1760 ± 86.7
SecondaryBuparlisib PK Parameter: Tmax at Cycle 1 Day 1

Summary of primary PK parameters for buparlisib plasma concentration

Time frame:
Cycle 1 Day 1 (each cycle is 28 days)
Reported as:
Median · hr
Buparlisib PK Parameter: Tmax at Cycle 1 Day 1
hrBuparlisib + Letrozole
Buparlisib PK Parameter: Tmax at Cycle 1 Day 11.03 (0.5 to 3.5)
SecondaryBuparlisib PK Parameter: AUClast at Cycle 4 Day 1

Summary of primary PK parameters for Buparlisib plasma concentration

Time frame:
0, 0.5, 1, 3, 6, 9 and 24 hours post-dose at Cycle 4 Day 1 (each cycle is 28 days)
Reported as:
Median · ng*hr/mL
Buparlisib PK Parameter: AUClast at Cycle 4 Day 1
ng*hr/mLBuparlisib + Letrozole
Buparlisib PK Parameter: AUClast at Cycle 4 Day 110400 (10400 to 10400)
SecondaryBuparlisb PK Parameter: Cmax at Cycle 4 Day 1

Summary of primary PK parameters for buparlisib plasma concentration

Time frame:
Cycle 4 Day 1 (each cycle is 28 days)
Reported as:
Median · ng/mL
Buparlisb PK Parameter: Cmax at Cycle 4 Day 1
ng/mLBuparlisib + Letrozole
Buparlisb PK Parameter: Cmax at Cycle 4 Day 1610 (610 to 610)
SecondaryBuparlisib PK Parameter: Tmax at Cycle 4 Day 1

Summary of primary PK parameters for buparlisib plasma concentration

Time frame:
Cycle 4 Day 1 (each cycle is 28 days)
Reported as:
Median · hr
Buparlisib PK Parameter: Tmax at Cycle 4 Day 1
hrBuparlisib + Letrozole
Buparlisib PK Parameter: Tmax at Cycle 4 Day 13 (3 to 3)

Adverse events

Collected over All Adverse Events reported in this record are on-treatment events (from first dose of study treatment to last dose of study treatment + 30 days, duration expected to be a total of approximately 25 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpelisib + Letrozole1/130 (0.8%)21/130 (16.2%)126/130 (96.9%)
Buparlisib + Letrozole0/81 (0%)22/81 (27.2%)80/81 (98.8%)
Placebo + Letrozole1/125 (0.8%)6/125 (4.8%)106/125 (84.8%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventAlpelisib + LetrozoleBuparlisib + LetrozolePlacebo + Letrozole
Alanine aminotransferase increasedInvestigations0/1307/810/125
Aspartate aminotransferase increasedInvestigations0/1306/810/125
HyperglycaemiaMetabolism and nutrition disorders7/1300/810/125
HepatotoxicityHepatobiliary disorders0/1303/810/125
Atrial fibrillationCardiac disorders0/1302/810/125
ColitisGastrointestinal disorders1/1302/810/125
RashSkin and subcutaneous tissue disorders3/1302/810/125
Rash maculo-papularSkin and subcutaneous tissue disorders2/1302/810/125
General physical health deteriorationGeneral disorders2/1301/810/125
PyrexiaGeneral disorders2/1300/810/125
Most frequent other events
Showing 10 of 55
Most frequent other events
EventAlpelisib + LetrozoleBuparlisib + LetrozolePlacebo + Letrozole
Alanine aminotransferase increasedInvestigations14/13049/813/125
Aspartate aminotransferase increasedInvestigations11/13044/812/125
HyperglycaemiaMetabolism and nutrition disorders69/13038/818/125
DiarrhoeaGastrointestinal disorders66/13029/8119/125
NauseaGastrointestinal disorders57/13037/8123/125
RashSkin and subcutaneous tissue disorders58/13031/8110/125
FatigueGeneral disorders53/13030/8142/125
StomatitisGastrointestinal disorders42/13018/815/125
Decreased appetiteMetabolism and nutrition disorders40/13025/8110/125
ArthralgiaMusculoskeletal and connective tissue disorders11/13013/8134/125

Baseline characteristics

The Full Analysis Set (FAS) comprised all randomized subjects in the study.

Age, Continuous
Age, Continuous(Years)Alpelisib + LetrozoleBuparlisib + LetrozolePlacebo + LetrozoleTotal
Mean64.3 ± 8.5365.2 ± 8.6163.1 ± 8.3164.1 ± 8.49
Sex: Female, Male
Sex: Female, Male(Participants)Alpelisib + LetrozoleBuparlisib + LetrozolePlacebo + LetrozoleTotal
Female13183126340
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alpelisib + LetrozoleBuparlisib + LetrozolePlacebo + LetrozoleTotal
White11768105290
Asian741021
Black or African American33511
Other36312
Unknown1236
08

Study locations

87 sites
  • University of Alabama at Birmingham/ Kirklin Clinic Univ AL - PI
    Birmingham, Alabama 35294-0006, United States
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • Los Angeles Hematology/Oncology Medical Group Onc Dept.
    Los Angeles, California 90017, United States
  • University of California at Los Angeles UCLA SC
    Los Angeles, California 90095, United States
  • University of California San Francisco BYL719A2201 - SC
    San Francisco, California 94115, United States
  • Emory University School of Medicine/Winship Cancer Institute SC
    Atlanta, Georgia 30322, United States
  • Mercy Medical Center Medical Oncology & Hematology
    Baltimore, Maryland 21202, United States
  • Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Johns Hopkins Med. BYL719A2201
    Baltimore, Maryland 21231, United States
  • Dana Farber Cancer Institute BYL719A2201
    Boston, Massachusetts 02215, United States
  • Mayo Clinic - Rochester BYL719A2201 - SC
    Rochester, Minnesota 55905, United States
  • Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Duke University Medical Center Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Northwest Cancer Specialists Vancouver Loc
    Portland, Oregon 97210, United States
  • Vanderbilt Ingram Cancer Center Vanderbilt Health 100 Oaks
    Nashville, Tennessee 37203, United States
  • Texas Oncology, P.A.
    Bedford, Texas 76022, United States
  • Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp
    Dallas, Texas 75231, United States
  • Texas Oncology Texas Oncology - Sammons
    Dallas, Texas 75246, United States
  • Texas Oncology Houston Memorial City SC
    Houston, Texas 77024, United States
  • Cancer Care Centers of South Texas HOAST CCC of So. TX- San Antonio(2)
    San Antonio, Texas 78229, United States
  • Cancer Therapy & Research Center UT Health Science Center InstituteForDrugDevelopment(5)
    San Antonio, Texas 78229, United States
  • Virginia Oncology Associates SC
    Norfolk, Virginia 23502, United States
  • Seattle Cancer Care Alliance SC-3
    Seattle, Washington 98105, United States
  • Northwest Medical Specialties Dept.ofNW Med. Specialties
    Tacoma, Washington 98405, United States
  • Novartis Investigative Site
    Kingswood, New South Wales 2747, Australia
  • Novartis Investigative Site
    Innsbruck, Tyrol 6020, Austria
  • Novartis Investigative Site
    Dornbirn, Vorarlberg 6830, Austria
  • Novartis Investigative Site
    Leoben, A-8700, Austria
  • Novartis Investigative Site
    Rankweil, A-6830, Austria
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    Vienna, A-1090, Austria
  • Novartis Investigative Site
    Villach, 9500, Austria
  • Novartis Investigative Site
    Wien, A-1090, Austria
  • Novartis Investigative Site
    Edegem, Antwerpen 2650, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Sint Niklaas, 9100, Belgium
  • Novartis Investigative Site
    Goiania, GO 74605-070, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Novartis Investigative Site
    Ribeirao Preto, SP 14048-900, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 01317-002, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 03102-002, Brazil
  • Novartis Investigative Site
    Shumen, 9700, Bulgaria
  • Novartis Investigative Site
    Sofia, 1303, Bulgaria
  • Novartis Investigative Site
    Varna, 9010, Bulgaria
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2W 1T8, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3T 1E2, Canada
  • Novartis Investigative Site
    Quebec, G1S 4L8, Canada
  • Novartis Investigative Site
    Medellin, Antioquia, Colombia
  • Novartis Investigative Site
    Bogota, Colombia
  • Novartis Investigative Site
    Olomouc, CZE 775 20, Czechia
  • Novartis Investigative Site
    Praha, 12808, Czechia
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Essen, 45136, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Koeln, 51067, Germany
  • Novartis Investigative Site
    Hong Kong SAR, Hong Kong
  • Novartis Investigative Site
    Haifa, 3525408, Israel
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
  • Novartis Investigative Site
    Tel Aviv, 64239, Israel
  • Novartis Investigative Site
    Brescia, BS 25127, Italy
  • Novartis Investigative Site
    Cremona, CR 26100, Italy
  • Novartis Investigative Site
    Macerata, MC 62100, Italy
  • Novartis Investigative Site
    Milano, MI 20141, Italy
  • Novartis Investigative Site
    Napoli, 80131, Italy
  • Novartis Investigative Site
    Nagoya-city, Aichi 467-8602, Japan
  • Novartis Investigative Site
    Hiroshima-city, Hiroshima 730-8518, Japan
  • Novartis Investigative Site
    Osaka-city, Osaka 540-0006, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8677, Japan
  • Novartis Investigative Site
    Koto-ku, Tokyo 135 8550, Japan
  • Novartis Investigative Site
    Niigata, 951-8566, Japan
  • Novartis Investigative Site
    Ashrafieh, 166830, Lebanon
  • Novartis Investigative Site
    Beirut, Lebanon
  • Novartis Investigative Site
    Saida, 652, Lebanon
  • Novartis Investigative Site
    Delft, 2625 AD, Netherlands
  • Novartis Investigative Site
    Den Haag, 2545 CH, Netherlands
  • Novartis Investigative Site
    Leiden, 2300 RC, Netherlands
  • Novartis Investigative Site
    Tilburg, 5022 GC, Netherlands
  • Novartis Investigative Site
    Sevilla, Andalucia 41017, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Hospitalet de LLobregat, Catalunya 08907, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46010, Spain
  • Novartis Investigative Site
    La Coruna, Galicia 15006, Spain
  • Novartis Investigative Site
    San Sebastián, Pais Vasco 20014, Spain
  • Novartis Investigative Site
    Madrid, 28007, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Madrid, 28050, Spain
09

References and documents

Publications

  • Mayer IA, Prat A, Egle D, Blau S, Fidalgo JAP, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz S, Estevez LG, van Dam PA, Kummel S, Mundhenke C, Holmes F, Babbar N, Charbonnier L, Diaz-Padilla I, Vogl FD, Sellami D, Arteaga CL. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clin Cancer Res. 2019 May 15;25(10):2975-2987. doi: 10.1158/1078-0432.CCR-18-3160. Epub 2019 Feb 5. PubMed 30723140 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jul 2017, 39 months.

Results were first posted in Sep 2018, 1 year 2 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 39 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2013
First posted
Aug 15, 2013
StartActual
Mar 11, 2014
Primary completionActual
Jul 7, 2017
CompletionActual
Jul 8, 2017
Results first posted
Sep 14, 2018
Last update
Sep 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01923168
Responsible party
Sponsor
First posted
Aug 15, 2013
Start date
Mar 11, 2014
Primary completion
Jul 7, 2017
Completion
Jul 8, 2017
Results posted
Sep 14, 2018
Last update
Sep 14, 2018

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alpelisib · Buparlisib

Start the discussion